



Date: January 07, 2024

To  
The Manager  
Corporate Relations Department  
BSE Limited  
Phiroze Jeejeebhoy Towers, Dalal Street  
Mumbai – 400001

Dear Sir/Madam,

**Scrip Code: 524572 | Scrip ID: PHARMAID | ISIN: INE117D01018**

**Sub: Issuance of Securities - Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”).**

With reference to the captioned subject, we would like to inform you that the Board of Directors at its Meeting held on Saturday, 06<sup>th</sup> January 2024, approved Issuance of up to 1,28,65,857 equity shares of the Company having face value of INR 10/- each to the Shareholders of Adita Bio Sys Private Limited on a preferential basis for consideration other than cash (Share swap) in the following manner:

- i. Considered and approved issue of equity shares upto 85,68,949 (Eighty-Five Lakh Sixty-Eight Thousand Nine Hundred Forty-Nine) No's of Equity Shares of the Company on Preferential Basis for Consideration other than Cash to the Individual shareholders of Adita Bio Sys Private Limited.
- ii. Considered and approved issuance of equity shares upto 15,74,650 (Fifteen Lakh Seventy-Four Thousand Six Hundred Fifty) No's of Equity Shares of the Company on Preferential Basis for Consideration other than Cash to Tumkur Trade Center Private Limited (a company registered under the Companies Act, 2013) one of the shareholders of Adita Bio Sys Private Limited.
- iii. Considered and approved issuance of equity shares upto 27,22,258 (Twenty-Seven Lakh Twenty-Two Thousand Two Hundred Fifty-Eight) No's of Equity Shares of the Company on Preferential Basis for Consideration other than Cash to Asian Hotels (Partnership Firm), one of the shareholders of Adita Bio Sys Private Limited.

Subject to the approval of the shareholders of the Company at the ensuing General Meeting of the Company and such other regulatory/ statutory approvals as may be required, the Board in aggregate of all the above issuance, has approved the issuance of upto 1,28,65,857 equity shares of the Company having a face value of INR 10/- each, for consideration other than cash in accordance with Chapter V of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 (“**ICDR Regulations**”), to the multiple existing



# Pharmaids Pharmaceuticals Limited

Shareholders of Adita Bio Sys Private Limited, discharged by the Company for the purchase of upto 99.94% of equity shares of Adita Bio Sys Private Limited (“Adita”), in accordance with the provisions of the Companies Act, 2013 and ICDR Regulations, as amended from time to time and other applicable laws.

The details required under Regulation 30 of the Listing Regulations read with the SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 on disclosure of material events/ information by listed entities, dated July 13, 2023 (SEBI Disclosure Circular) in respect of the aforesaid preferential issue are enclosed herewith as **Annexure A**.

Kindly take the same on your record and oblige.

Thanking You

**For Pharmaids Pharmaceuticals Limited**

**Kaushik Kumar**  
**(Company Secretary & Head-Legal)**



**Disclosures in terms of Regulation 30 of the Listing Regulations read with the SEBI Disclosure Circular, in respect of Issue of equity shares of the Adita**

| Sr. No | Particulars  | Details  |
|--------|--|--|
| a      | Type of securities proposed to be issued (viz. equity shares, convertibles, etc.)  | Equity Shares  |
| b      | Type of issuance (further public offering, rights issue, depository receipts (ADR/GDR), qualified institutions placement, preferential allotment etc.) | Preferential allotment of equity shares for a non cash consideration, i.e. on a share swap basis, in accordance with Regulation 163(3) of the ICDR Regulations.  |
| c      | Total number of securities proposed to be issued or the total amount for which the securities will be issued (approximately).                          | Up to 1,28,65,857 fully paid-up equity shares of the Company having a face value of Rs. 10.00 (Rupee Ten Only) each.   |
| d      | Names of the investors   | Individual Shareholders:<br>1. Sourappa Samuel Sharmanraj<br>2. Swathi H V<br>3. Manjunath N S<br>4. Chethan Basavaraju<br>5. KR Raghunatha Reddy<br>6. Keshava Murthy S<br>7. H S Usha Rani<br>8. Prakash G<br>9. Gokaram Ramkrishna Balaji<br>10. Paramesh Kiran Kumar<br>11. Saritha Chandra<br>12. N Avinash<br>13. Raghavendra N<br>14. R Ashok<br>15. A Balakrishna<br>16. Sapna Y R<br>17. Jayalakshmi R<br>18. Shivakumar K J<br>19. P Janardhana<br>20. M Sreevalli<br>21. V Mahendra<br>22. Shilpa Raghavendra |



# Pharmaids Pharmaceuticals Limited

|   |                     |   |
|---|---------------------|---|
|   |                     | 23. M D Venkatesh<br>24. Shreedhara Shetty<br>25. G R Dheemanth<br>26. Irudia Raj Sathyendra<br><br>Company:<br>27. Tumkur trade Center Private Limited<br><br>Partnership firm:<br>28. Asian Hotels  |
| e | Issue price         | The equity shares shall be issued at a price that is not less than the higher of the following:<br><br>a) the floor price as on the Relevant Date determined in accordance with Chapter V of ICDR Regulations and<br>b) the fair value per equity share of the Company as on the Relevant Date, determined based on the Valuation Report. |
| f | Number of investors | 28  |

**For Pharmaids Pharmaceuticals Limited**

**Kaushik Kumar**  
**(Company Secretary & Head-Legal)**